Key Takeaways:
- Caris Life Sciences (CAI) develops molecular profiling and AI-driven technologies to support precision medicine in oncology, with Q4 2025 revenue of $292.9 million, up 2.3x year over year.
- CAI stock has pulled back around 29% year to date, creating a potential entry point for investors who believe in the precision oncology growth story.
- CAI stock could rise from $19 to around $37 per share by December 2028, implying a 93.6% total return.
- That works out to around 28.2% in annualized returns over the next 2.6 years, a level the model considers highly attractive.
What Happened?
Caris Life Sciences, Inc. (CAI) is one of the newest publicly traded companies in precision oncology. The stock was listed with significant excitement but has pulled back around 29% year to date. Despite the price decline, the underlying business is building operational momentum. Caris is deploying AI and molecular profiling technology to transform how cancer is diagnosed and treated.
In early May 2026, Caris received MolDX approval for its ChromoSeq test for myeloid malignancies. Myeloid malignancies are blood cancers, including leukemia and related disorders. This approval opens an entirely new clinical market for Caris beyond its solid tumor profiling core. The company also validated an AI signature that predicts which glioblastoma patients will benefit from a chemotherapy drug called temozolomide.
Caris reported Q4 2025 revenue of $292.9 million, up 2.3x year over year. The company secured a $400 million term loan from Blue Owl Capital and Blackstone in April 2026 to fund continued growth. Caris is also advancing its Detect multi-cancer early detection test, which showed 56.8% Stage I sensitivity in interim clinical data. A collaboration with Genentech adds further commercial and clinical credibility to the platform.
Investors are weighing substantial long-term upside potential against near-term profitability pressure. Operating margins remain thin as the company invests heavily in clinical studies and regulatory filings. But the pace of regulatory wins and clinical validations is accelerating.
Here’s why Caris Life Sciences stock could deliver exceptional long-term returns for investors who are willing to accept near-term volatility.
What the Model Says for CAI Stock
We analyzed the upside potential for Caris Life Sciences stock based on its rapidly scaling molecular profiling platform, expanding AI-driven oncology applications, and accelerating regulatory approval cadence.
Based on estimates of 20.7% annual revenue growth, 5.6% operating margins, and a normalized P/E multiple of 136.6x, the model projects Caris Life Sciences’ stock could rise from $19 to around $37 per share.
That would be a 93.6% total return, or a 28.2% annualized return over the next 2.6 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for CAI stock:
1. Revenue Growth: 20.7%
Caris Life Sciences reported Q4 2025 revenue of $292.9 million, up 2.3x year over year. The company is scaling its molecular profiling tests across oncology centers, hospital networks, and research partnerships. Revenue growth is being driven by new test launches, new cancer indications, and broadening clinical adoption across the portfolio.
The MolDX approval for ChromoSeq adds myeloid malignancy profiling to the platform. The Detect MCED test is progressing through clinical validation and could represent a large new revenue stream. These new products are not incremental additions but represent fundamentally new markets that Caris is entering.
Based on analysts’ consensus estimates, we used 20.7% annual revenue growth. The forward two-year consensus revenue CAGR stands at approximately 23.0%, so our assumption is slightly conservative relative to the analyst community. It reflects rapid scaling momentum while acknowledging the inherent uncertainty of early-stage test launches.
2. Operating Margins: 5.6%
Caris currently operates with a 5.6% EBIT margin and a strong 66.6% gross margin. The high gross margin shows genuine pricing power and favorable unit economics in molecular profiling services. But investments in clinical studies, lab infrastructure, and regulatory submissions are keeping net margins thin at this early stage.
The $400 million term loan from Blue Owl Capital and Blackstone provides the capital to fund continued platform investment. This financing will support new test launches, partnership development, and expanded clinical validation programs. Short-term profitability will remain modest as this investment phase continues through the next several years.
Based on analysts’ consensus estimates, we used 5.6% operating margins. This reflects the current cost structure as Caris scales its platform and executes its clinical roadmap. As test volumes grow and laboratory utilization improves, margins should expand materially, and the high gross margin should begin to flow through to the bottom line.
3. Exit P/E Multiple: 136.6x
CAI currently trades at a forward NTM P/E of 136.56x. This elevated multiple reflects the market’s expectation of rapid future earnings growth from a very small current earnings base. Companies in early-stage precision medicine often carry high multiples because the earnings power is still in an early building phase.
The analyst’s target of around $30 implies roughly 55% upside from the current $19 price. This gap reflects the analyst’s conviction in the long-term platform value. But the high multiple also means the stock carries meaningful valuation risk if revenue growth decelerates or operating margin expansion is slower than expected.
Based on analysts’ consensus estimates, we used a 136.6x exit P/E multiple. This assumes the market continues to price Caris as a high-growth precision medicine platform company. Any meaningful compression in this multiple from a growth disappointment would significantly reduce the projected total return.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for CAI stock through 2034 show varied outcomes based on molecular profiling test adoption, regulatory approval pace, and AI-driven oncology platform scale (these are estimates, not guaranteed returns):
- Low Case: Revenue growth trails expectations and multi-cancer test adoption is slower than planned → around 30% annual returns
- Mid Case: ChromoSeq, Detect, and Genentech collaboration scale according to plan → around 33% annual returns
- High Case: AI diagnostic capabilities will accelerate rapidly across new cancer indications → around 41% annual returns
Going forward, Caris Life Sciences’ stock will be driven by the pace of test adoption, the clinical validation of Detect, and the expansion of AI-driven oncology applications. The model projects strong returns across all three scenarios, which reflects the early-stage growth premium the market assigns to precision oncology platforms.
Investors should monitor each regulatory approval and clinical data readout closely, as these events are the primary catalysts that will drive the stock’s re-rating over time.
See what analysts think about CAI stock right now (Free with TIKR) >>>
Should You Invest in Caris Life Sciences?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CAI, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CAI alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Caris Life Sciences stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
